Anxiety and depression symptoms after COVID-19 infection: results from the COVID Symptom Study app.
COVID-19
depression
psychiatry
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
08
07
2021
accepted:
07
09
2021
pubmed:
30
9
2021
medline:
1
12
2021
entrez:
29
9
2021
Statut:
ppublish
Résumé
Mental health issues have been reported after SARS-CoV-2 infection. However, comparison to prevalence in uninfected individuals and contribution from common risk factors (eg, obesity and comorbidities) have not been examined. We identified how COVID-19 relates to mental health in the large community-based COVID Symptom Study. We assessed anxiety and depression symptoms using two validated questionnaires in 413148 individuals between February and April 2021; 26998 had tested positive for SARS-CoV-2. We adjusted for physical and mental prepandemic comorbidities, body mass index (BMI), age and sex. Overall, 26.4% of participants met screening criteria for general anxiety and depression. Anxiety and depression were slightly more prevalent in previously SARS-CoV-2-positive (30.4%) vs SARS-CoV-2-negative (26.1%) individuals. This association was small compared with the effect of an unhealthy BMI and the presence of other comorbidities, and not evident in younger participants (≤40 years). Findings were robust to multiple sensitivity analyses. Association between SARS-CoV-2 infection and anxiety and depression was stronger in individuals with recent (<30 days) versus more distant (>120 days) infection, suggesting a short-term effect. A small association was identified between SARS-CoV-2 infection and anxiety and depression symptoms. The proportion meeting criteria for self-reported anxiety and depression disorders is only slightly higher than prepandemic.
Sections du résumé
BACKGROUND
Mental health issues have been reported after SARS-CoV-2 infection. However, comparison to prevalence in uninfected individuals and contribution from common risk factors (eg, obesity and comorbidities) have not been examined. We identified how COVID-19 relates to mental health in the large community-based COVID Symptom Study.
METHODS
We assessed anxiety and depression symptoms using two validated questionnaires in 413148 individuals between February and April 2021; 26998 had tested positive for SARS-CoV-2. We adjusted for physical and mental prepandemic comorbidities, body mass index (BMI), age and sex.
FINDINGS
Overall, 26.4% of participants met screening criteria for general anxiety and depression. Anxiety and depression were slightly more prevalent in previously SARS-CoV-2-positive (30.4%) vs SARS-CoV-2-negative (26.1%) individuals. This association was small compared with the effect of an unhealthy BMI and the presence of other comorbidities, and not evident in younger participants (≤40 years). Findings were robust to multiple sensitivity analyses. Association between SARS-CoV-2 infection and anxiety and depression was stronger in individuals with recent (<30 days) versus more distant (>120 days) infection, suggesting a short-term effect.
INTERPRETATION
A small association was identified between SARS-CoV-2 infection and anxiety and depression symptoms. The proportion meeting criteria for self-reported anxiety and depression disorders is only slightly higher than prepandemic.
Identifiants
pubmed: 34583944
pii: jnnp-2021-327565
doi: 10.1136/jnnp-2021-327565
pmc: PMC8599635
mid: NIHMS1743174
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1254-1258Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : EPA
ID : EP-W-17-011
Pays : United States
Organisme : NIDDK NIH HHS
ID : K01 DK120742
Pays : United States
Organisme : NIDDK NIH HHS
ID : K23 DK125838
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: AM, CH, AG, SS and JW are employees of Zoe Limited. TDS reports being a consultant for Zoe Limited during the conduct of the study. ATC previously served as an investigator on a separate study supported by Zoe Limited.
Références
Brain Behav Immun. 2020 Oct;89:531-542
pubmed: 32485289
Lancet Psychiatry. 2021 May;8(5):416-427
pubmed: 33836148
Brain. 2020 Oct 1;143(10):3104-3120
pubmed: 32637987
Cell. 2020 Oct 1;183(1):16-27.e1
pubmed: 32882182
Nat Rev Immunol. 2020 Nov;20(11):645-646
pubmed: 33024283
Neurology. 2020 Sep 29;95(13):e1868-e1882
pubmed: 32680942
Nat Rev Neurol. 2020 Nov;16(11):636-644
pubmed: 32839585
Br J Psychiatry. 2020 Oct 21;:1-8
pubmed: 33081860
EClinicalMedicine. 2021 Jan 07;31:100683
pubmed: 33490928
Lancet Psychiatry. 2020 Jul;7(7):611-627
pubmed: 32437679
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
BJPsych Open. 2021 May 18;7(3):e104
pubmed: 34001295
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Lancet Psychiatry. 2020 Oct;7(10):875-882
pubmed: 32593341
Nat Neurosci. 2021 Feb;24(2):168-175
pubmed: 33257876
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Nat Neurosci. 2021 Mar;24(3):368-378
pubmed: 33328624
Med Care. 2003 Nov;41(11):1284-92
pubmed: 14583691
Lancet Psychiatry. 2020 Oct;7(10):883-892
pubmed: 32707037